Neogenomics (NEO) Operating Income (2016 - 2025)
Historic Operating Income for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to -$27.0 million.
- Neogenomics' Operating Income fell 2744.26% to -$27.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$120.9 million, marking a year-over-year decrease of 3098.1%. This contributed to the annual value of -$92.1 million for FY2024, which is 1450.77% up from last year.
- Latest data reveals that Neogenomics reported Operating Income of -$27.0 million as of Q3 2025, which was down 2744.26% from -$47.6 million recorded in Q2 2025.
- In the past 5 years, Neogenomics' Operating Income ranged from a high of -$15.1 million in Q1 2021 and a low of -$52.0 million during Q1 2022
- In the last 5 years, Neogenomics' Operating Income had a median value of -$27.8 million in 2025 and averaged -$30.5 million.
- As far as peak fluctuations go, Neogenomics' Operating Income tumbled by 95056.76% in 2021, and later surged by 3876.23% in 2023.
- Quarter analysis of 5 years shows Neogenomics' Operating Income stood at -$41.6 million in 2021, then skyrocketed by 36.53% to -$26.4 million in 2022, then grew by 29.6% to -$18.6 million in 2023, then grew by 0.93% to -$18.4 million in 2024, then plummeted by 46.81% to -$27.0 million in 2025.
- Its Operating Income was -$27.0 million in Q3 2025, compared to -$47.6 million in Q2 2025 and -$27.8 million in Q1 2025.